Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV002428087 | SCV002730199 | uncertain significance | Hereditary cancer-predisposing syndrome | 2022-10-18 | criteria provided, single submitter | clinical testing | The p.V741I variant (also known as c.2221G>A), located in coding exon 10 of the BRCA2 gene, results from a G to A substitution at nucleotide position 2221. The valine at codon 741 is replaced by isoleucine, an amino acid with highly similar properties. This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
University of Washington Department of Laboratory Medicine, |
RCV002428087 | SCV003846588 | likely benign | Hereditary cancer-predisposing syndrome | 2023-03-23 | criteria provided, single submitter | curation | Missense variant in a coldspot region where missense variants are very unlikely to be pathogenic (PMID:31911673). |
All of Us Research Program, |
RCV004007408 | SCV004835368 | uncertain significance | Breast-ovarian cancer, familial, susceptibility to, 2 | 2023-11-30 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV005098016 | SCV005812920 | uncertain significance | Hereditary breast ovarian cancer syndrome | 2024-07-02 | criteria provided, single submitter | clinical testing | This sequence change replaces valine, which is neutral and non-polar, with isoleucine, which is neutral and non-polar, at codon 741 of the BRCA2 protein (p.Val741Ile). This variant is present in population databases (no rsID available, gnomAD 0.003%). This missense change has been observed in individual(s) with a personal or family history of cancer (PMID: 29310832). ClinVar contains an entry for this variant (Variation ID: 1787940). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt BRCA2 protein function with a negative predictive value of 95%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |